Alzinova AB (publ) (STO:ALZ)

Market Cap	70.89M -62.2%
Revenue (ttm)	25.66M +28.0%
Net Income	-26.58M
EPS	n/a
Shares Out	154.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	592,487
Open	0.4510
Previous Close	0.4415
Day's Range	0.4380 - 0.4730
52-Week Range	0.3820 - 2.2800
Beta	0.97
Analysts	n/a
Price Target	2.30 (+402.73%)
Earnings Date	Aug 20, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. The company’s lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alz...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ALZ

Financial Performance

In 2025, Alzinova AB's revenue was 26.80 million, an increase of 59.44% compared to the previous year's 16.81 million. Losses were -26.27 million, 27.8% more than in 2024.